Treatment of advanced prostate cancer - if, when and what?

Poster Session 04

  • Location:
    Room Amsterdam, North Hall (Level 1)
  • Chairs:
     S. Bracarda, Arezzo (IT)
     P. Cornford, Liverpool (GB)
     A.S. Merseburger, Lübeck (DE)
  • Aims and objectives of this session

    Data about new and established approaches for systemic treatment of prostate cancer and management of nodal disease will be presented. Differential indication of hormone ablation versus other forms of systemic treatments will be discussed together with long-term effects of androgen deprivation therapy.

  • Poster viewing of 20 minutes. Presentations will take place on stage. Standard presentations are 2 minutes in length, followed by 2 minutes for discussion.
Improved survival in patients diagnosed with metastatic prostate cancer – a nationwide analysis

By: Helgstrand J.T.1, Klemann N.1, Toft B.2, Vainer B.2, Brasso K.1, Brooks J.3, Iversen P.1, Røder M.1

Institutes: 1Copenhagen University Hospital, Rigshospitalet, Copenhagen Prostate Cancer Center, Dept. of Urology, Copenhagen, Denmark, 2Copenhagen University Hospital, Rigshospitalet, Dept. of Pathology, Copenhagen, Denmark, 3Stanford University Hospital, Dept. of Urology, Stanford, United States of America

What is the optimal post-operative management of men with lymph node recurrent prostate cancer after salvage lymph node dissection? Results from a large, multi-institutional series

By: Briganti A.1, Fossati N.1, Suardi N.1, Bandini M.1, Colicchia M.6, Karnes J.R.6, Haidl F.7, Pfister D.7, Porres D.7, Heidenreich A.7, Herlemann A.9, Gratzke C.9, Stief C.9, Battaglia A.4, Everaerts W.4, Joniau S.4, Van Poppel H.4, Aksenov A.V.8, Osmonov D.K.8, Jünemann K.P.8, Abreu A.D.L.3, Almeida F.3, Fay C.2, Gill I.2, Mottrie A.M.5, Montorsi F.1

Institutes: 1Vita-Salute University San Raffaele, Dept. of Urology, Milan, Italy, 2Keck School of Medicine, University of Southern California, USC Institute of Urology, Los Angeles, United States of America, 3Phoenix Imaging Center, Dept. of Urology, Phoenix, United States of America, 4University Hospitals Leuven, Dept of Development and Regeneration, Leuven, Belgium, 5OLV Ziekenhuis Aalst, Dept. of Urology, Melle, Belgium, 6Mayo Clinic, Dept. of Urology, Rochester, United States of America, 7University of Cologne, Dept. of Urology, Cologne, Germany, 8University Hospital Schleswig Holstein, Dept. of Urology and Pediatric Urology, Campus Kiel, Germany, 9Ludwig-Maximilians-University, Dept. of Urology, Munich, Germany

Salvage lymph node dissection in nodal recurrent prostate cancer is not devoid of complications: Results from a single tertiary referral center

By: Dell’Oglio P.1, Gandaglia G.1, Stabile A.1, Fossati N.1, Bianchi M.2, Bravi C.1, Zaffuto E.1, Bandini M.1, Fallara G.1, Gallina A.1, Suardi N.1, Rigatti P.3, Montorsi F.1, Briganti A.1

Institutes: 1Vita-Salute University San Raffaele, Dept. of Urology, Milan, Italy, 2Magna Graecia University, Dept. of Urology, Catanzaro, Italy, 3Advanced Urotechnology Center, Scientific Institute “Istituto Auxologico Italiano”, Dept. of Urology, Milan, Italy

Phase III study of intermittent monotherapy versus continuous combined androgen deprivation

By: Calais Da Silva Junior F.1, Calais Da Silva Senior F.1, Gonçalves F.2, Kliment J.3, Santos A.4, Pastidis S.5, Queimadelos A.6, Robertson C.7

Institutes: 1CHLC – Hospital de São José, Dept. of Urology, Lisbon, Portugal, 2CUIMED A Saint Michal Hospital, Dept. of Urology, Bratislava, Slovakia, 3Jessenius Schooll of Medicine, Dept. of Urology, Martin, Slovakia, 4Hospital De Braga, Dept. of Urology, Braga, Portugal, 5Amalia Fleming Hospital, Dept. of Urology, Athens, Greece, 6Policlinica La Rosaleda, Dept. of Urology, Santiago Compostela, Spain, 7University of Stracthclyde, Dept. of Urology, Glasgow, United Kingdom

Chemical castration decreased the risk of dementia in patients with prostate cancer - from 13368 patients, Taiwan National Health Insurance Research Database

By: Hong J., Liao C., Huang C., Lu Y.

Institutes: National Taiwan University Hospital, Dept. of Urology, Taipei, Taiwan

Testosterone recovery after long time androgen deprivation therapy: The role of duration of deprivation in combination with other predictive factors

By: Estrada-Domínguez F.2, Borque Fernando A.1, Esteban L.3, Gil Sanz M.J.4, Sanz Saiz G.5

Institutes: 1Hospital Universitario Miguel Servet, Dept. of Uology, Zaragoza, Spain, 2Hospital Universitario “Miguel Servet” (IIS Aragón), Dept. of Urology, Zaragoza, Spain, 3Universidad De Zaragoza, Escuela Universitaria Politécnica De La Almunia, Zaragoza, Spain, 4Hospital Universitario Miguel Servet, Dept. of Urology, Zaragoza, Spain, 5Universidad De Zaragoza, Dept. of Statistical Methods, Zaragoza, Spain

Survival following primary androgen deprivation therapy or watchful waiting among older men with localized prostate cancer

By: Seikkula H.1, Boström P.2, Rantanen M.3, Pitkäniemi J.3, Malila N.3, Kaipia A.4

Institutes: 1Central Hospital of Central Ostrobothnia, Dept. of Urology, Kokkola, Finland, 2Turku University Hospital, Dept. of Urology, Turku, Finland, 3Finnish Cancer Registry, Institute For Statistical and Epidemiological Cancer Research, Helsinki, Finland, 4Satakunta Hospital District, Dept. of Urology, Pori, Finland

Does prostate cancer represent the main cause of death in all node positive prostate cancer patients? The impact of competing causes of mortality according to tumor characteristics and recurrence status

By: Dell’Oglio P.1, Zaffuto E.1, Stabile A.1, Gandaglia G.1, Colicchia M.2, Fossati N.1, Capitanio U.1, Dehò F.1, Colombo R.1, Bertini R.1, Montorsi F.1, Karnes J.2, Briganti A.1

Institutes: 1Vita-Salute University San Raffaele, Dept. of Urology, Milan, Italy, 2Mayo Clinic, Dept. of Urology, Rochester, United States of America

Radium-223 (Ra-223) in sequence or in concurrent use with abiraterone acetate (AA) or enzalutamide (E) in metastatic castration resistant prostate cancer (mCRPC) patients treated in an international early access program (iEAP)

By: Saad F.1, Heinrich D.2, Gillessen S.3, O’Sullivan J.4, Carles J.5, Wirth M.6, Miller K.7, Huang L.8, Seger M.9, Nilsson S.10, Heidenreich A.11

Institutes: 1University of Montreal Hospital Center, Dept. of GU Oncology, Montréal, Canada, 2Akershus University Hospital,, Dept. of Oncology, Lørenskog, Norway, 3Kantonsspital St Gallen,, Dept. of Oncology, St Gallen, Switzerland, 4The Northern Ireland Cancer Centre, Dept. of Radiation Oncology, Belfast, United Kingdom, 5Vall D’ Hebron University Hospital,, Dept. of Medical Oncology, Barcelona, Spain, 6University Hospital Carl-Gustav Carus, Dept. of Urology, Dresden, Germany, 7Charité University Medicine Berlin, Dept. of Urology, Berlin, Germany, 8Pharmaceutical Division of Bayer, Dept. of Statistics, Whippany, United States of America, 9Pharmaceutical Division of Bayer, Dept. of Global Medical Affairs, Whippany, United States of America, 10Karolinska University Hospital, Dept. of Oncology, Stockholm, Sweden, 11University Hospital Cologne, Dept. of Urology, Cologne, Germany

The importance of imaging studies to monitor treatment with novel AR-targeted agents in metastatic castration resistant prostate cancer (mCRPC)

By: Heidegger I., Kohl T., Pfister D., Friederike H., Paffenholz P., Heidenreich A.

Institutes: Uniklinik Köln, Dept. of Urology, Cologne, Germany

Does nadir testosterone at the end of long term androgen deprivation therapy predict outcomes in high risk prostate cancer? Data from a phase III trial

By: Nabid A.1, Garant M-P.2, Martin A-G.3, Souhami L.4, Duclos M.4, Bahary J-P.5, Lemaire C.6, Vass S.7, Archambault R.8, Vincent F.9, Bahoric B.11, Bettahar R.10

Institutes: 1Centre Hospitalier Universitaire de Sherbrooke, Dept. of Radio-Oncology, Sherbrooke, Canada, 2Centre Hospitalier Universitaire de Sherbrooke, Biostatistical Services, Sherbrooke, Canada, 3Centre Hospitalier Universitaire de Québec, Dept. of Radio-Oncology, Québec, Canada, 4Centre Universitaire de Santé McGill, Dept. of Radio-Oncology, Montréal, Canada, 5Centre Hospitalier Universitaire de Montréal, Dept. of Radio-Oncology, Montréal, Canada, 6Hôpital Maissonneuve-Rosemont, Dept. of Radio-Oncology, Montréal, Canada, 7Centre de Santé et Services Sociaux de Chicoutimi, Dept. of Radio-Oncology, Chicoutimi, Canada, 8Hôpital De Gatineau, Dept. of Radio-Oncology, Gatineau, Canada, 9Centre Hospitalier Régional de Trois-Rivières, Dept. of Radio-Oncology, Trois-Rivières, Canada, 10Centre Hospitalier Régional de Rimouski, Dept. of Radio-Oncology, Rimouski, Canada, 11Hôpital Général Juif de Montréal, Dept. of Radio-Oncology, Montréal, Canada

Semi-ecologic, nationwide, population-based study of GnRH agonists, orchiectomy and risk of cardiovascular disease

By: Stattin P.1, Thomsen F.B.2, Sandin F.3, Garmo H.4, Ahlgren G.5, Lissbrant I.F.6, Van Hemelrijck M.4, Adolfsson J.7, Robinson D.8

Institutes: 1Uppsala University Hospital, Dept. of Surgical Sciences, Uppsala, Sweden, 2Rigshospitalet, University of Copenhagen, Copenhagen Prostate Cancer Center, Dept. of Urology, Copenhagen, Denmark, 3Uppsala University Hospital, Regional Cancer Centre Uppsala Örebro, Uppsala, Sweden, 4King’s College London, School of Medicine, Dept. of Cancer Studies, Cancer Epidemiology Group, London, United Kingdom, 5SUS Malmö, Dept. of Urology, Malmö, Sweden, 6University of Gothenburg, Dept. of Oncology, Gothenburg, Sweden, 7Karolinska Institutet, CLINTEC-Dept, Stockholm, Sweden, 8Umeå University Hospital, Dept. of Surgical and Perioperative Sciences, Umeå, Sweden

Advanced prostate cancer - A wide range of treatment options and challenges
 A.S. Merseburger, Lübeck (DE)